Hyderabad, November 17: Sai Parenterals Limited has approved the acquisition of a majority stake in Hyderabad-based Bion Therapeutics through its wholly owned subsidiary, SP Analytics, though the exact value hasn’t been revealed. The all cash transaction has been approved by the company’s board and is expected to close by the end of November 2026.
Under the terms, SP Analytics will be acquiring a majority stake in Bion Therapeutics, making it a step-down subsidiary of Sai Parenterals. By acquiring this company, Sai Parenterals will gain a portfolio of 16 branded formulations, including Meaxon, MITOQ7, Adgaba, Sunlite and LG Bion in therapeutic segments including neuropathy, mitochondrial health, pain management and wound care. Bion has carved its niche by building its brand through direct engagement with doctors.
This is expected to give Sai Parenterals a direct access to the broader market, strengthening its competitive position in the domestic pharmaceutical market, after it acquired a stake in injectable pharma brand Prathyak Labs in October.
Bion’s existing management team will continue to lead the business after the acquisition, while retaining the market knowledge and doctor relationships it currently has.
“Bion has built both over nearly two decades, power brands led by Meaxon and MITO Q7 Plus, a presence across twelve states and a field organisation of two hundred and fifty people engaging with twenty thousand doctors. A franchise of this nature is established over many years, and it comes to us intact, the brands, the relationships and the organisation that sustains them.
This acquisition completes the platform we have been building. Over the past year we have expanded capacity at Unit III, begun construction of the critical-care injectable facility at Gummadidala, consolidated all our research at Sai Prathyak, and strengthened the Noumed platform in Australia and New Zealand. Each of these strengthens what we are able to develop and manufacture. Bion provides the route to take them to the Indian market directly, converting development capability into branded revenue.
The value flows in both directions. Bion’s portfolio, presently manufactured by third parties, will transfer to our accredited facilities, improving supply assurance, quality control and margin. In turn, our development pipeline and Noumed’s dossier library give Bion’s field organisation a materially wider portfolio to take to market. We will disclose the further particulars of the transaction at the appropriate stage.” Mr. Anil Kumar Karusala, Chairman and Managing Director, Sai Parenterals Limited, said in a press release.
“Bion’s brands have been built on clinical credibility and sustained engagement with the medical community. Our therapeutic focus, neuropathy, diabetes supportive care, mitochondrial health, wound care and pain management, has allowed us to establish depth in the segments that matter to us, rather than breadth for its own sake.
Joining the Sai Parenterals Group addresses the constraint we have felt most acutely: access to manufacturing depth and a development pipeline at the scale our market position warrants. Our team will continue to lead the business and its relationships. What changes is the breadth of the portfolio they are able to take to market.” Mr. Laxman Prasad Shukla, Managing Director, Bion Therapeutics India Private Limited, added.

